Type 2 Diabetes Treatment 2026: New NICE Guidelines Explained

Type 2 diabetes treatment is changing. For many years, blood sugar was the main focus. The 2026 NICE update still cares about blood glucose, but it puts much more weight on the whole person: heart health, kidney health, weight, frailty, pregnancy safety, treatment burden, and access to medicines.

Direct answer: NICE updated its type 2 diabetes in adults guideline on February 18, 2026. The biggest practical shift is that many adults are now recommended an SGLT-2 inhibitor early in treatment, often with modified-release metformin, while medicine choices are tailored to heart failure, cardiovascular disease, kidney disease, obesity, early-onset diabetes, frailty, safety, and personal preferences.

This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. If you have symptoms, a medical condition, or questions about your care, speak with a qualified healthcare professional.

Seek urgent medical help if symptoms are severe, sudden, worsening, or feel life-threatening. For people with diabetes, urgent warning signs can include confusion, fainting, seizures, severe weakness, trouble breathing, chest pain, repeated vomiting, signs of dehydration, very low blood sugar, high ketones, or symptoms of diabetic ketoacidosis. DKA can be life-threatening and can occur in people with type 2 diabetes, although it is more common in type 1 diabetes.

Quick summary

• NICE guideline NG28 was last updated on February 18, 2026 and covers care and management for adults aged 18 and over with type 2 diabetes.
• NICE now recommends that adults with type 2 diabetes and no relevant comorbidity are offered modified-release metformin and an SGLT-2 inhibitor as initial medicines, unless metformin is contraindicated or not tolerated.
• Medicine choices are now more explicitly shaped by heart failure, atherosclerotic cardiovascular disease, early-onset type 2 diabetes, obesity, chronic kidney disease, frailty, pregnancy potential, and treatment safety.
• This is UK NICE guidance. It is highly relevant for UK readers, but people in the US, Canada, Australia, and Europe should follow local guidance and speak with their own clinician.

Key Takeaway

The 2026 NICE update is not a reason to change diabetes medicine on your own. It is a signal that type 2 diabetes care is becoming more personalised, with earlier attention to heart and kidney protection, treatment safety, weight, frailty, pregnancy planning, and shared decision-making.

What is NICE, and why does this update matter?

NICE stands for the National Institute for Health and Care Excellence. It produces evidence-based guidance used across health and care services in England, and its guidance is also closely watched by clinicians, policymakers, and health writers internationally.

The updated NICE guideline is NG28: Type 2 diabetes in adults: management. NICE says the guideline covers adults aged 18 and over with type 2 diabetes and focuses on education, dietary advice, cardiovascular risk, blood glucose management, and identifying and managing long-term complications.

The 2026 update matters because it reflects a broader view of type 2 diabetes treatment. Instead of asking only, “How do we lower HbA1c?” clinicians are encouraged to ask:

• Does this person have heart failure?
• Do they have cardiovascular disease?
• Do they have kidney disease?
• Are they living with obesity?
• Did type 2 diabetes develop early in adult life?
• Are they frail or at higher risk of side effects?
• Could pregnancy or breastfeeding be relevant?
• Is the treatment realistic, safe, affordable, and acceptable for this person?

That does not mean blood sugar no longer matters. It means blood sugar is one part of a wider risk picture.

What changed in the 2026 NICE type 2 diabetes treatment guidance?

The most reader-relevant changes are in medicines, sick-day planning, safety, and individualised care.

1. SGLT-2 inhibitors move earlier in treatment

For adults with type 2 diabetes and no relevant comorbidity, NICE now says clinicians should offer:

• modified-release metformin, and
• an SGLT-2 inhibitor.

If metformin is contraindicated or not tolerated, NICE recommends monotherapy with an SGLT-2 inhibitor for this group.

This is a major shift from older “metformin first, then add another medicine later” thinking. NICE’s quality standard was also updated in February 2026 so that its quality statement on SGLT-2 inhibitor treatment now includes all adults with type 2 diabetes, while still requiring individual circumstances and risks to be considered.

2. Modified-release metformin is now central for many people

NICE recommends modified-release metformin in several initial treatment pathways, including people with no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, obesity, chronic kidney disease when kidney function allows, and frailty.

For people already taking standard-release metformin, NICE says clinicians may continue it, or switch to modified-release metformin if standard-release metformin is not tolerated or if the person prefers the switch.

This is not a message to change your prescription yourself. It is a discussion point for your next diabetes review.

3. Heart, kidney, and weight issues influence medicine choice

NICE states that SGLT-2 inhibitors and GLP-1 receptor agonists are recommended as much for their cardiovascular and renal benefits as for their blood glucose benefits, unless the guideline specifies otherwise.

For example:

• For people with heart failure, NICE recommends modified-release metformin and an SGLT-2 inhibitor, or an SGLT-2 inhibitor alone if metformin is contraindicated or not tolerated.
• For people with atherosclerotic cardiovascular disease, NICE recommends modified-release metformin, an SGLT-2 inhibitor, and subcutaneous semaglutide up to the specified dose for cardiovascular, renal, and blood glucose benefits.
• For people with chronic kidney disease, recommendations vary by estimated glomerular filtration rate, or eGFR, which is a blood-test-based measure of kidney function.
• For people with frailty, NICE is more cautious about SGLT-2 inhibitors if frailty increases the risk of adverse events such as volume depletion or low blood pressure.

What are SGLT-2 inhibitors?

SGLT-2 inhibitors are medicines that help the kidneys remove extra glucose through urine. In type 2 diabetes care, they are used for blood glucose management and, in selected people, for heart and kidney protection.

Common medicines in this class include dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin. MHRA safety information notes that SGLT-2 inhibitors available in the UK include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.

The important safety point: SGLT-2 inhibitors are not suitable for everyone. NICE says individual circumstances should be considered, including kidney function, pregnancy or breastfeeding, frailty, and risk of diabetic ketoacidosis.

SGLT-2 inhibitor safety: what readers should know

The 2026 NICE update puts safety planning front and center.

Before starting an SGLT-2 inhibitor, NICE recommends checking whether a person may be at increased risk of diabetic ketoacidosis, including previous DKA, current illness, dehydration risk, or following a very low-carbohydrate or ketogenic diet. NICE also says modifiable DKA risks should be addressed before starting treatment.

NICE advises that people taking an SGLT-2 inhibitor should speak with a healthcare professional before starting a very low-carbohydrate or ketogenic diet because such diets can increase DKA risk, and SGLT-2 treatment may need to be suspended during that diet under clinical direction.

The MHRA advises healthcare professionals to interrupt SGLT-2 inhibitor treatment in patients hospitalised for major surgery or acute serious illness, monitor ketones during that period, preferably in blood, and restart treatment only once ketones are normal and the person’s condition has stabilised.

For readers, the safe takeaway is not “avoid these medicines.” It is: know the warning signs, follow your clinician’s sick-day plan, and do not combine SGLT-2 inhibitor use with extreme diet changes or illness management decisions without professional advice.

GLP-1 medicines and tirzepatide: where they fit

GLP-1 receptor agonists and tirzepatide are injectable medicines used in some people with type 2 diabetes. Some are also used for weight management under specific approvals and eligibility rules. They can affect blood glucose and weight, and some medicines in these groups have evidence for cardiovascular or kidney-related benefits in selected populations.

In the 2026 NICE guideline, GLP-1 receptor agonists and tirzepatide appear in specific pathways, not as a blanket recommendation for everyone.

Examples include:

• For adults with early-onset type 2 diabetes, NICE recommends modified-release metformin and an SGLT-2 inhibitor, and says clinicians should consider adding either a GLP-1 receptor agonist for cardiovascular, renal, and blood glucose benefits, or tirzepatide for blood glucose benefits.
• For adults with type 2 diabetes who are living with obesity, NICE says clinicians may consider adding a GLP-1 receptor agonist or tirzepatide if initial therapy has been taken for at least 3 months, further medicine is needed to reach individualised blood glucose targets, and the person is not already taking one of these medicines.
• NICE says GLP-1 receptor agonists and tirzepatide should not be used together with a DPP-4 inhibitor to treat type 2 diabetes.

Pregnancy safety is especially important. NICE says that when discussing GLP-1 receptor agonists and tirzepatide with women, trans men, and non-binary people of childbearing potential, clinicians should explain MHRA guidance on pregnancy and breastfeeding, that weight loss may improve fertility, that effective contraception must be used, and that contraception should continue for a period after stopping the medicine before trying to become pregnant.

What happens if first medicines are not enough?

NICE still uses a stepwise approach. It recommends introducing medicines one at a time, checking tolerability and effectiveness. When a person starts metformin and other medicines, NICE says metformin should be introduced first, then an SGLT-2 inhibitor once metformin is at the maximum tolerated dose, and then a GLP-1 receptor agonist or tirzepatide once the SGLT-2 inhibitor is at the maximum tolerated dose when these medicines are part of the plan.

If more medicine is needed later, NICE recommendations depend on the person’s health profile.

For people with no relevant comorbidity who need further medicine to reach individualised targets, NICE recommends adding a DPP-4 inhibitor first, then considering a sulfonylurea, pioglitazone, or insulin-based treatment if needed and appropriate.

For people with frailty, NICE is more cautious. It recommends considering a DPP-4 inhibitor, and says clinicians should take into account that sulfonylureas and insulin-based treatments can increase the risk of hypoglycaemia and falls.

What about insulin?

Insulin remains an important treatment for some people with type 2 diabetes, especially when other medicines are not enough, symptoms are significant, or individual circumstances require it.

NICE says adults with type 2 diabetes starting insulin should receive a structured education programme. This should include injection technique, self-monitoring, dose titration to target levels, dietary advice, driving guidance, managing hypoglycaemia, managing acute changes in glucose, and support from a healthcare professional trained in insulin therapy.

NICE recommends basal insulin intended for once- or twice-daily use as initial insulin therapy for adults with type 2 diabetes. In some situations, especially if HbA1c is 75 mmol/mol, or 9.0%, or higher, clinicians may consider combining basal insulin with short- or rapid-acting insulin.

This does not mean insulin is a “failure.” It means diabetes needs can change over time.

HbA1c targets: still individual, not one-size-fits-all

HbA1c is a blood test that reflects average blood glucose over roughly the past few months. NICE recommends measuring HbA1c every 3 to 6 months until stable on unchanged therapy, then every 6 months once HbA1c and glucose-lowering therapy are stable.

NICE says clinicians should discuss and agree an individual HbA1c target with adults with type 2 diabetes. It also says targets may need to be relaxed case by case, especially for people who are older or frailer, people less likely to benefit from long-term risk reduction, or people at high risk from hypoglycaemia.

This is a key safety point. A “lower” number is not always better if getting there causes dangerous lows, falls, stress, or poor quality of life.

Diet, weight, and remission: what NICE says in 2026

The 2026 NICE surveillance review looked at dietary interventions for type 2 diabetes and decided to update the guideline to cross-refer to recommendations on low-calorie diets in NICE’s overweight and obesity management guideline.

NICE recommends individualised and ongoing nutritional advice from a healthcare professional with specific nutrition expertise. It also recommends healthy eating advice that includes high-fibre, low-glycaemic-index carbohydrate sources such as fruit, vegetables, wholegrains, and pulses; low-fat dairy products; oily fish; and controlling saturated and trans fats.

NICE also says dietary advice should be integrated with a personalised diabetes management plan, including physical activity and weight management where relevant.

The safe message: do not start a very-low-calorie, very-low-carbohydrate, ketogenic, fasting, or extreme diet without clinical advice, especially if you take insulin, a sulfonylurea, an SGLT-2 inhibitor, are pregnant, have kidney disease, have an eating disorder history, or are frail.

What readers can safely do now

If you have type 2 diabetes and hear about the 2026 NICE update, do not panic and do not change your medicine yourself.

Instead, use it to prepare for a safer, more informed conversation.

You can ask your clinician:

• “Does the 2026 NICE update apply to my situation?”
• “Do I have heart, kidney, weight, frailty, or pregnancy-related factors that affect medicine choice?”
• “Should my treatment plan include an SGLT-2 inhibitor, or is there a reason it may not be suitable for me?”
• “Do I have written sick-day rules?”
• “What should I do if I am vomiting, dehydrated, fasting, having surgery, or unable to eat normally?”
• “What are the warning signs of low blood sugar or ketoacidosis for my medicines?”
• “Do I need a review of my HbA1c target?”

Guidance may vary by country, so check local health services or speak with a clinician. NICE guidance is especially relevant in the UK. In the US, clinicians often use the American Diabetes Association Standards of Care, which publishes annually updated clinical practice recommendations.

Common mistakes to avoid

Mistake 1: Changing medicine after reading a headline.
The NICE update is for clinician-guided care. Do not start, stop, switch, or reduce diabetes medicine without professional advice.

Mistake 2: Thinking all adults should be treated exactly the same.
The update is more personalised, not less. Heart disease, kidney function, frailty, pregnancy potential, weight, side effects, cost, and preferences all matter.

Mistake 3: Starting a ketogenic diet while taking an SGLT-2 inhibitor without advice.
NICE warns that very low-carbohydrate or ketogenic diets can increase DKA risk for people taking SGLT-2 inhibitors, and treatment may need to be managed differently under clinical guidance.

Mistake 4: Assuming GLP-1 medicines are only weight-loss drugs.
Some GLP-1 medicines are used for type 2 diabetes, some for weight management, and some for specific risk profiles. Suitability depends on the exact medicine, indication, health history, pregnancy plans, and local approval.

Mistake 5: Chasing a lower HbA1c at any cost.
NICE supports individual HbA1c targets and allows relaxed targets in some higher-risk situations, especially when tight control may cause hypoglycaemia or reduce quality of life.

Biology made simple: why diabetes treatment is no longer only about sugar

Type 2 diabetes affects how the body uses insulin, the hormone that helps move glucose from the blood into cells. Over time, high glucose can contribute to damage in blood vessels and nerves.

But type 2 diabetes is also closely linked with other risks: heart disease, kidney disease, weight-related complications, fatty liver disease, blood pressure problems, and frailty in some older adults.

That is why modern diabetes care often asks more than, “What lowers glucose?” It asks:

• What protects the heart?
• What protects the kidneys?
• What is least likely to cause low blood sugar?
• What fits this person’s daily life?
• What risks matter most for this person?
• What treatment is safe during illness, pregnancy planning, or surgery?

The 2026 NICE update reflects that broader thinking.

Composite example, not a real patient

Aisha, 58, has type 2 diabetes and early chronic kidney disease. She has taken standard-release metformin for years but often gets stomach upset. She reads about the 2026 NICE update and wonders if she should stop metformin and order a newer medicine online.

Instead, she books a medication review. Her clinician checks her kidney function, heart history, HbA1c, blood pressure, other medicines, and side effects. They discuss whether modified-release metformin would be easier to tolerate, whether an SGLT-2 inhibitor is appropriate, and what sick-day rules she should follow if she becomes dehydrated or needs surgery.

The lesson: the update is useful because it supports a better review, not because it gives Aisha a do-it-yourself treatment plan.

Myth vs Fact

Myth: NICE now says everyone must take the same diabetes drugs.
Fact: NICE recommends broad treatment pathways, but it repeatedly emphasizes individualised care, shared decision-making, comorbidities, safety, frailty, pregnancy considerations, and patient preferences.

Myth: Metformin is no longer used.
Fact: Metformin remains central in many NICE treatment pathways, especially modified-release metformin. People already tolerating standard-release metformin may continue it.

Myth: SGLT-2 inhibitors are only for people with kidney or heart disease.
Fact: NICE’s 2026 recommendations expand SGLT-2 inhibitor use to more adults with type 2 diabetes, including those with no relevant comorbidity, while still requiring attention to safety and individual circumstances.

Myth: If you take a newer diabetes medicine, diet and activity no longer matter.
Fact: NICE still recommends ongoing dietary advice, healthy living, physical activity, and personalised diabetes management alongside medicines.

Myth: A low HbA1c is always the goal.
Fact: NICE recommends individual targets and says targets may need to be relaxed in some people, especially if tight control increases risk or harms quality of life.

When to see a doctor or qualified clinician

Arrange a diabetes review if:

• You have not had your medication reviewed since the February 2026 NICE update.
• You have heart failure, cardiovascular disease, kidney disease, obesity, frailty, or early-onset type 2 diabetes.
• You have side effects from metformin or other diabetes medicines.
• You take an SGLT-2 inhibitor and do not have written sick-day rules.
• You are planning pregnancy, could become pregnant, are pregnant, or are breastfeeding.
• You are considering a ketogenic, very low-carbohydrate, fasting, or very-low-calorie diet.
• Your HbA1c is above target, below target with symptoms, or you have frequent low blood sugar.
• You are starting insulin or using insulin and having lows, falls, or driving concerns.

Seek urgent medical help for symptoms such as severe confusion, seizure, fainting, repeated vomiting, trouble breathing, chest pain, high ketones, severe dehydration, or severe low blood sugar needing help from another person. CDC notes that low blood sugar can be dangerous if untreated, and severe low blood sugar may cause confusion, seizures, fainting, and need help from someone else.

Smart questions to ask a clinician

1. “Which NICE 2026 treatment pathway best fits me: no relevant comorbidity, heart failure, cardiovascular disease, kidney disease, obesity, early-onset diabetes, or frailty?”
2. “What are my personal risks and benefits with SGLT-2 inhibitors, GLP-1 medicines, tirzepatide, DPP-4 inhibitors, sulfonylureas, pioglitazone, or insulin?”
3. “Can we write down sick-day rules, low blood sugar instructions, and when I should seek urgent care?”

FAQs

1. What is the biggest change in the 2026 NICE type 2 diabetes guidance?
The biggest practical change is earlier and broader use of SGLT-2 inhibitors, often alongside modified-release metformin, while medicine choice is tailored to heart, kidney, weight, frailty, pregnancy, and personal safety factors. The update moves diabetes care further beyond blood sugar alone.

2. Does this mean I should ask for an SGLT-2 inhibitor?
You can ask whether an SGLT-2 inhibitor is appropriate for you, but do not start one without a clinician. Suitability depends on kidney function, frailty, dehydration risk, DKA risk, pregnancy or breastfeeding, current medicines, and your overall health situation.

3. Is modified-release metformin better than standard metformin?
NICE now recommends modified-release metformin in many initial treatment pathways. For people already taking standard-release metformin, NICE says they can continue it or switch if it is not tolerated or if they prefer. Your clinician can help decide what makes sense for you.

4. Are GLP-1 medicines and tirzepatide part of the new NICE guidance?
Yes, but only in specific pathways. NICE discusses GLP-1 receptor agonists and tirzepatide for selected groups, such as early-onset type 2 diabetes or type 2 diabetes with obesity when further medicine is needed. Pregnancy potential, contraception, side effects, and other medicines need careful review.

5. Does NICE guidance apply outside the UK?
NICE guidance is written for the UK health system, especially England. Readers in the US, Canada, Australia, and Europe can learn from it, but local approvals, prescribing rules, insurance coverage, and clinical guidelines differ. Ask a local clinician before making any treatment decision.

Written by:
Ibrahim Abdo, Health Content Specialist and Evidence-Based Medical Writer focused on translating complex health information into clear, trustworthy, reader-friendly insights.

Medical review status:
Not medically reviewed. This article was editorially fact-checked and is for educational purposes only.

Published:
May 1, 2026

Sources:
Sources are listed below and were checked for direct relevance to the medical claims in this article.

Last updated:
May 1, 2026

Editorial standard:
This article was created using evidence-based sources and reviewed for clarity, accuracy, and reader safety.

Sources

1. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management. NICE guideline NG28.” https://www.nice.org.uk/guidance/ng28. Published: December 2, 2015. Last updated/reviewed: February 18, 2026. Accessed: May 1, 2026.
   Supports: Overall scope of NICE NG28, adult type 2 diabetes management, and confirmation of the February 2026 update.
2. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — Initial medicines.” https://www.nice.org.uk/guidance/ng28/chapter/Initial-medicines. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Initial medicine recommendations for modified-release metformin, SGLT-2 inhibitors, heart failure, atherosclerotic cardiovascular disease, early-onset diabetes, obesity, chronic kidney disease, and frailty.
3. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — Person-centred medicine.” https://www.nice.org.uk/guidance/ng28/chapter/Person-centred-medicine. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Shared decision-making, healthy living alongside medicines, pregnancy and contraception discussions for GLP-1 medicines and tirzepatide, sick-day rules, cardiovascular and renal risk assessment, and SGLT-2 access inequalities.
4. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — How to introduce medicines.” https://www.nice.org.uk/guidance/ng28/chapter/How-to-introduce-medicines. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Stepwise medicine introduction and DKA risk checks before SGLT-2 inhibitor treatment.
5. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — Reviewing medicines.” https://www.nice.org.uk/guidance/ng28/chapter/Reviewing-medicines. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Reviewing metformin, continuing SGLT-2 inhibitors for cardiovascular or renal benefits, stopping GLP-1 receptor agonists or tirzepatide in defined circumstances, and not combining GLP-1 receptor agonists or tirzepatide with DPP-4 inhibitors.
6. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — Further medication.” https://www.nice.org.uk/guidance/ng28/chapter/Further-medication. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Additional medication pathways when glycaemic targets are not met, including DPP-4 inhibitors, sulfonylureas, pioglitazone, GLP-1 receptor agonists, tirzepatide, and insulin-based treatment.
7. National Institute for Health and Care Excellence. “Type 2 diabetes in adults: management — Insulin-based treatments.” https://www.nice.org.uk/guidance/ng28/chapter/Insulin-based-treatments. Last updated: February 18, 2026. Accessed: May 1, 2026.
   Supports: Structured education when starting insulin, insulin initiation principles, basal insulin, basal-bolus considerations, and insulin safety review.
8. National Institute for Health and Care Excellence. “Type 2 diabetes in adults. NICE quality standard QS209.” https://www.nice.org.uk/guidance/qs209/resources/type-2-diabetes-in-adults-pdf-75547422824389. Updated: February 2026. Accessed: May 1, 2026.
   Supports: Updated quality statement on SGLT-2 inhibitor prescribing for adults with type 2 diabetes and safety considerations including kidney function, pregnancy, breastfeeding, frailty, and DKA risk.
9. Medicines and Healthcare products Regulatory Agency. “SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness.” https://www.gov.uk/drug-safety-update/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness. Published: March 18, 2020. Accessed: May 1, 2026.
   Supports: SGLT-2 inhibitor DKA safety advice, ketone monitoring during major surgery or acute serious illness, and restart conditions.
10. Medicines and Healthcare products Regulatory Agency. “GLP-1 medicines for weight loss and diabetes: what you need to know.” https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know. Published: June 5, 2025. Last updated: February 5, 2026. Accessed: May 1, 2026.
    Supports: GLP-1 medicine safety, pregnancy and contraception guidance, side effects, and public safety information.
11. Centers for Disease Control and Prevention. “Low Blood Sugar (Hypoglycemia).” https://www.cdc.gov/diabetes/about/low-blood-sugar-hypoglycemia.html. Published/Updated: May 16, 2024. Accessed: May 1, 2026.
    Supports: Hypoglycaemia warning signs, severe low blood sugar, and urgent safety context.
12. Centers for Disease Control and Prevention. “Diabetic Ketoacidosis.” https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html. Published/Updated: May 15, 2024. Accessed: May 1, 2026.
    Supports: DKA overview, seriousness, life-threatening risk, and relevance to people with type 2 diabetes.